The truth about invisible posterior vitreous structures

Publication
Article
Ophthalmology Times EuropeOphthalmology Times Europe December 2022
Volume 18
Issue 10

Understanding vitreomacular interface diseases is key to treatment.

With the development of optical coherence tomography (OCT), subtle changes in the posterior vitreous can be observed that are not clearly visible by slit lamp biomicroscopy. With the advent of swept-source OCT (SS-OCT) technology in particular, variations in normal changes can now be visualised, as well as those associated with ageing.

In most normal eyes, the premacular lacuna and connected Cloquet’s canal can be clearly detected by SS-OCT (Figure 1). However, these structures become less noticeable with advancing patient age. The contours of the premacular lacuna collapse, and the liquefaction of the vitreous gel progresses.

Figure 1. OCT image of 39-year-old woman shows premacular lacuna and Cloquet’s canal. Top: Premacular lacuna (*) and connected Cloquet’s (**) canal can be clearly detected. Bottom: The same case of top image with vertical and horizontal scales on a 1:1 scale.

Figure 1. OCT image of 39-year-old woman shows premacular lacuna and Cloquet’s canal. Top: Premacular lacuna (*) and connected Cloquet’s (**) canal can be clearly detected. Bottom: The same case of top image with vertical and horizontal scales on a 1:1 scale.

Figure 2. OCT image of 63-year-old woman does not show premacular lacuna and Cloquet’s canal. Premacular lacuna and Cloquet’s canal become inconspicuous because of age-related change of the vitreous.

Figure 2. OCT image of 63-year-old woman does not show premacular lacuna and Cloquet’s canal. Premacular lacuna and Cloquet’s canal become inconspicuous because of age-related change of the vitreous.

In cases in which the premacular lacuna and Cloquet’s canal are not visible (Figure 2) and in which advanced vitreous liquefaction is present, a presumed bursa premacularis/posterior pre-cortical vitreous pocket (PPVP) appears (Figure 3).

Figure 3. OCT image of 56-year-old man shows Bursa premacularis coexisting with premacular lacuna/subbursal space and connected Cloquet’s canal. Presumed Bursa premacularis/posterior vitreous pocket appears (***) with premacular lacuna/subbursal space (*) and connected Cloquet’s canal (**) .

Figure 3. OCT image of 56-year-old man shows Bursa premacularis coexisting with premacular lacuna/subbursal space and connected Cloquet’s canal. Presumed Bursa premacularis/posterior vitreous pocket appears (***) with premacular lacuna/subbursal space (*) and connected Cloquet’s canal (**) .

Occasionally, the premacular lacuna and bursa fuse into a large empty space (Figure 4, upper right; Figure 5, right).

Differentiation of the premacular lacuna and the bursa premacularis/PPVP is important. Early studies found that the bursa premacularis/PPVP is a liquefied space with a relatively large volume, and not a thin space like the premacular lacuna.1,2

In usual OCT examinations, the depth is emphasised (Figure 1, top) and the premacular lacuna looks relatively large. However, when viewing the premacular lacuna with vertical and horizontal scales on a 1:1 scale in young patients (Figure 1, bottom), the premacular lacuna is almost the same depth as the thickness of the retina.

The premacular lacuna seems to correspond to a sub-bursal space, referred to in one in vivo slit lamp microscopy study and later as an artefact.3 However, it is my opinion that the premacular lacuna corresponds to a sub-bursal space.

Posterior vitreous detachments

Details of the early phase of age-related posterior vitreous detachments (PVDs) were previously unknown because they were not visible by biomicroscopy, however, SS-OCT has furthered the understanding of these detachments.

Figure 4. Early phase of PVD progression. PVD progression begins from the state of No PVD (upper left) to the vicinity of the outer periphery of the macula (bottom left), then PVD spreads throughout the posterior pole (upper right). In many cases, an oval defect in the posterior vitreous cortex is formed (middle or lower right), and the thin posterior vitreous cortex remains on the macular retina (blue arrow). Among them, there are two types of shallow PVD with an oval defect in the posterior vitreous cortex. Shallow PVD with vitreous gel attachment to the macula through the premacular oval defect of posterior vitreous cortex (middle right) and no vitreous gel attachment to the macula (bottom right).

Figure 4. Early phase of PVD progression. PVD progression begins from the state of No PVD (upper left) to the vicinity of the outer periphery of the macula (bottom left), then PVD spreads throughout the posterior pole (upper right). In many cases, an oval defect in the posterior vitreous cortex is formed (middle or lower right), and the thin posterior vitreous cortex remains on the macular retina (blue arrow). Among them, there are two types of shallow PVD with an oval defect in the posterior vitreous cortex. Shallow PVD with vitreous gel attachment to the macula through the premacular oval defect of posterior vitreous cortex (middle right) and no vitreous gel attachment to the macula (bottom right).

Age-related PVD progression begins from the state of no PVD to the vicinity of the outer periphery of the macula, as seen in the OCT image on the upper left to lower left of Figure 4.4 The PVD progresses throughout the posterior pole, but it is relatively rare for the condition to progress without showing an oval defect in the detached posterior vitreous cortex (Figure 4, upper right).

In many cases, the oval defect in the posterior vitreous cortex forms as shown in the middle or lower right, and the thin posterior vitreous cortex remains on the macular retina. There are two types of shallow PVD with an oval defect in the posterior vitreous cortex: one with vitreous gel attachment to the macula through the premacular oval defect of the posterior vitreous cortex (Figure 4, middle right),5,6 and one with no vitreous gel attachment to the macula (Figure 4, bottom right).

Figure 5. Mechanism of macular hole development. OCT findings clearly show that Shallow PVD, which leaves pinpoint adhesion in the fovea (left), is the cause of macular hole (right).

Figure 5. Mechanism of macular hole development. OCT findings clearly show that Shallow PVD, which leaves pinpoint adhesion in the fovea (left), is the cause of macular hole (right).

The condition of vitreous attachment through the oval defect in the posterior vitreous cortex may be experienced during creation of a PVD during vitreous surgery. This type of PVD is thought to provide protection for the fovea, where the retina is thin and fragile. The failure to make such a circular defect in the posterior vitreous cortex may induce the development of macular holes in some cases (Figure 5).

The structure that was defined as a bursa has many variations in ageing. When the bursa fuses with the premacular lacuna/ sub-bursal premacular space, it appears as a large empty space. There are some variations in PVDs starting in the posterior pole, but some of them are related to macular holes and epiretinal membranes, so detailed observation is indispensable.

Figure 6. Vitreous attachment through the oval defect in posterior vitreous cortex observed during PVD creation in vitreous surgery. After core vitrectomy, artificial posterior vitreous detachment is created using triamcinolone. The vitreous gel adhesion to the macula through the oval defect in the posterior vitreous cortex is clearly seen. (All images courtesy of Dr Akihiro Kakehashi)

Figure 6. Vitreous attachment through the oval defect in posterior vitreous cortex observed during PVD creation in vitreous surgery. After core vitrectomy, artificial posterior vitreous detachment is created using triamcinolone. The vitreous gel adhesion to the macula through the oval defect in the posterior vitreous cortex is clearly seen. (All images courtesy of Dr Akihiro Kakehashi)

Although these descriptions are based on my personal experience and opinion, I hope they increase clinicians’ understanding of vitreomacular interface diseases.

Akihiro Kakehashi, MD, PhD
E: kakeaki@gmail.com
Dr Kakehashi is based at the Department of Ophthalmology, Saitama Medical Center, Jichi Medical University in Saitama, Japan. He has no financial interest in any aspect of this article.
References
1. Worst JG. Cisternal systems of the fully developed vitreous body in the young adult. Trans Ophthalmol Soc UK (1962). 1977;97:550-554.
2. Kishi S, Shimizu K. Posterior precortical vitreous pocket. Arch Ophthalmol. 1990;108:979-982.
3. Worst JG. Posterior precortical vitreous pocket. Arch Ophthalmol. 1991;109:1058- 1060.
4. Kakehashi A, Takezawa M, Akiba J. Classification of posterior vitreous detachment. Clin Ophthalmol. 2014;8:1-10.
5. Kakehashi A, Ishiko S, Konno S, et al. Observing the posterior vitreous by means of the scanning laser ophthalmoscope. Arch Ophthalmol. 1995;113:558-560.
6. Kakehashi A, Schepens CL, Trempe CL. Vitreomacular observations. I. Vitreomacular adhesion and hole in the premacular hyaloid. Ophthalmology. 1994;101:1515-1521.
Recent Videos
Quan Dong Nguyen, MD, MSc, of the Byers Eye Institute at Stanford University School of Medicine, discusses his presentation on Stargardt disease at the American Academy of Ophthalmology meeting
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
At EURETINA 2024, Martin S. Zinkernagel, MD, PhD, on the future of real-world AI use
Related Content
© 2024 MJH Life Sciences

All rights reserved.